A humanized ossicle platform for real-time tracking and preclinical assessment of CAR-based immunotherapies in acute myeloid leukemia
Samantha DonsanteiD, Mara Algeri, Marta BiondiiD, Vanessa ZambelliiD, Carlotta GuzzettiiD, Erica GrassenisiD, Gaia Alberti, Emanuele RezoagliiD, Sarah TettamantiiD, Andrea BiondiiD, Mara RiminucciiD, Alice PievaniiD, Marta SerafiniiD
Abstract
Preclinical evaluation of chimeric antigen receptor (CAR)-T therapies for acute myeloid leukemia (AML) is limited by the lack of models that faithfully recapitulate the human bone marrow (BM) niche. Here, we implemented a humanized ossicle-based AML model that enables simultaneous engraftment of leukemic blasts and longitudinal assessment of responses to CAR-based immunotherapies. Intravenous or intra-ossicle injection of AML blasts produced robust, reproducible disease mimicking features of human AML within its microenvironment. To monitor tumor burden and immune effector cells in real-time, we developed a dual bioluminescence system using distinct luciferases in AML and CAR-T cells. This approach allowed non-invasive longitudinal tracking of CAR-T cell localization, expansion, persistence, and leukemic clearance within the ossicle. Overall, our model provides a powerful platform to study CAR-T cell behavior within a human BM niche and, for the first time, allows simultaneous longitudinal visualization of leukemic burden and CAR-T cell dynamics in a physiologically relevant ossicle-based AML model. TeaserHumanized ossicles combined with dual BLI enable tracking of AML progression and CAR-T cell dynamics in a human stromal niche.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Engineering autologous ossicles for the personalized modeling of acute myeloid leukemia
Camille Sauter, Dimitra Zacharaki, … Paul Emile Bourgine·bioRxiv·Jun 2, 2026
- Synthetic peptide hydrogels as a model of the bone marrow niche demonstrate efficacy of a combined CRISPR-CAR T-cell therapy for acute myeloid leukaemia
W. Sebastian Doherty-Boyd, Penelope M. Tsimbouri, … Hannah Donnelly·BiomaterialsPeer-reviewed·Oct 26, 2025
- Bicistronic CAR T-cells Against CD70 & Active Integrin β2 Overcome Antigen Heterogeneity and Preserve Safety in Acute Myeloid Leukemia
Amrik S. Kang, H. A. Johnson, … Arun P. Wiita·bioRxiv·Sep 21, 2025
- Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid Leukemia
D. Sanchez Martinez, N. Tirado, … P. Menendez·bioRxiv·Mar 15, 2022
- Multi-Niche Human Bone Marrow On-A-Chip for Studying the Interactions of Adoptive CAR-T Cell Therapies with Multiple Myeloma
Delta Ghoshal, Ingrid Petersen, … Krishnendu Roy·bioRxiv·Apr 8, 2024
- Base edited "universal" donor CAR T cell strategies for acute myeloid leukaemia
Renuka Kadirkamanathan, Christos Georgiadis, … Waseem Qasim·LeukemiaPeer-reviewed·Oct 1, 2025